Analysts Report Brexit Will be Beneficial for Cryptocurrency Values

With Brexit causing a financial turmoil in the country, experts opine that cryptocurrencies and other digital assets will grow in value in the region

Brexit is currently shrouded by uncertainties. While no individual or organization is sure about the terms which will be agreed upon, or if there will be any, most are of the opinion that it is bound to happen. UK Prime Minister, Theresa May, has resigned after her re-proposal (of an already rejected proposal), was turned down as well. The most likely event, is that the deadline for the event, will be extended, so that they can come to an appropriate arrangement for financial trade, with the European Union. However, currently the country’s economy is in a sorry state of affairs, although, that may translate into a boom for cryptocurrency.

Ever since the motion for Brexit was passed in 2016, the country has been losing GBP 800 million on a weekly basis. The GBP value went to new lows as compared to the US Dollar, and the Euro. A financial analysis firm has stated that approximately 275 finance companies have exited the country, in the wake of the decision. Historically, cryptocurrencies are known to thrive in times of economic crisis.

Analysts project that Britain, post-Brexit, will have much friendlier regulations on cryptocurrency and digital assets. However, some analysts also have contrasting opinions. They believe that a government restructure, could possibly delay the necessary framework for cryptocurrency transactions.

“Almost 44% of analysts believe Brexit would not affect crypto regulation in the UK.​Under a no deal scenario, withdrawing from the EU would lead to a repeal of the ECA. This would effectively remove 17,105 legal instruments across many areas of law, thus creating serious complications for the UK legislative system. After Brexit, the government3would then need to focus directly on legal processes associated with traditional political, economic and financial issues.” Says a report from financial intelligence firm, Cindicator.

Disease Control and Prevention Vaccine Market Trends and Growth 2026: Top Players Serum Institute of India Pvt. Ltd., and Daiichi Sankyo

The Global Disease Control and Prevention Vaccine Market, by Product Type (Live-Attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), by Type (Monovalent and Multivalent), By Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), By Indication (Infectious Disease, Cancer and Other Indications) was valued US$ 41.12 billion in 2017 and is projected to exhibit a CAGR of 12.1% over the forecast period (2017 – 2025) as highlighted in a new report published by Coherent Market Insights. New product launches by market players coupled with rising government immunization programs are the major factors driving growth of the global disease control and prevention vaccine market over the forecast period.

Request Sample Copy Of This Report:

Vaccines aid in control and prevention of viral and bacterial disease. Vaccines for infectious disease has large impact on reducing disease incidence and burden of vaccine preventable disease. According to Centers for Disease Control and Prevention (CDC), in 2013, around 226,000 people are hospitalized every year and between 3,000 and 49,000 people die due to influenza and its complications. The global efforts to tackle infectious disease by better surveillance and immunization system enhanced effectiveness of the immunization program. For instance, according to World Health Organization (WHO), incidence of polio are decreased by 99% as of 2018 as compare to 1988, attributed to global initiatives for polio eradication by public and private organizations. Furthermore, increasing government initiative to strengthen immunization program are expected to augment the growth of disease control and prevention vaccine market. For instance, in 2017, Minister of Health from 194 countries endorsed Global Vaccine Action Plan to prevent millions of death through more access to vaccine by 2020. Moreover, manufacturers are focusing on the developing new vaccine with better safety and immunity for the disease at low cost.

Some of the major players involved in global disease control and prevention vaccine market include GlaxoSmithKline plc (GSK), Merck & Co. Inc., Sanofi, AstraZeneca PLC, Pfizer, Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Astellas Pharma Inc., and Daiichi Sankyo

Research Test Severe Limitations of Deep Learning Machines

Researchers from University of California – Los Angeles stated that deep convolutional networks do not classify based on global object shape

A team of researchers from University of California – Los Angeles (UCLA) conducted five experiments on Deep Convolutional Networks (DCNNs) and found that it is easy to fool the networks and that the networks’ method of identifying objects with the help of computer vision differs substantially from human vision. In the first experiment, the team showed VGG-19— one of the best deep learning networks—color images of animals and objects. The images had been altered. For instance, the surface of a golf ball was displayed on a teapot. The network ranked its top choices and chose the correct item as its first choice for only five of 40 objects.

Moreover, VGG-19 stated that there was only a 0.41% chance the teapot was a teapot and its first choice for the teapot was a golf ball. Lead author Nicholas Baker, a UCLA psychology graduate student stated that this shows that the Artificial Intelligence network observes the texture of an object more so than its shape. According to Philip Kellman, a UCLA distinguished professor of psychology and a senior author of the study, humans identify objects primarily from their shape however, the computer networks are more likely using a different method. In the second experiment, the team showed images of glass figurines to VGG-19 and AlexNet. Both networks were trained to recognize objects with help of an image database called ImageNet. Although VGG-19 performed better than the other network, both networks were inefficient in identifying the glass figurines.

In the third experiment, the team showed 40 drawings outlined in black, with images in white, to both the networks. The networks again failed to identify items such as a butterfly, an airplane, and a banana.  The fourth experiment included 40 images in solid black. Both the networks produced the correct object label among their top five choices for around 50% of the objects. In the final experiment, the team scrambled the images to increase the difficulty level. However, pieces of the objects were preserved. Six images correctly recognized by VGG-19 earlier were scrambled. The team found that these images were hard to recognize for themselves, whereas VGG-19 recognized five of the six images and was close on the sixth. The research was published in the journal PLOS Computational Biology on December 07, 2018.

New Materials Can Drive Wound Healing By Harnessing Natural Healing Methods

New materials can drive wound healing by harnessing natural healing methods, according to a report published on January 7, 2019.

Dr. Ben Almquist and his team at Imperial College London created a new molecule that helps the way in which traditional materials work with the body. The newly developed materials are known as traction force-activated payloads (TrAPs), which are capable of talking to the body’s natural repair systems to drive healing. According to the researchers, integration of TrAPs into existing medical materials could revolutionize the way injuries are treated. The findings of the study were published in Advanced Materials.

The researchers designed TrAPs as a way to recreate this natural healing method. The DNA segments were folded into three-dimensional shapes known as aptamers that cling tightly to proteins. A customizable handle that cells can grab was attached onto on one end, before attaching the opposite end to a scaffold such as collagen. When the technique was tested in the laboratory, they found that cells pulled on the TrAPs as they crawled through the collagen scaffolds. The pulling made the TrAPs unravel like shoelaces to reveal and activate the healing proteins. These proteins instruct the healing cells to grow and multiply.

As this approach can be adapted to various cell types, it can be used in a variety of injuries such as fractured bones, scar tissue after heart attacks, and damaged nerves. TrAPs are relatively straightforward to create and are fully man-made, which makes scaling up of these to industrial quantities easier.

Dr. Almquist said, “The TrAP technology provides a flexible method to create materials that actively communicate with the wound and provide key instructions when and where they are needed. This sort of intelligent, dynamic healing is useful during every phase of the healing process, has the potential to increase the body’s chance to recover, and has far-reaching uses on many different types of wounds. This technology has the potential to serve as a conductor of wound repair, orchestrating different cells over time to work together to heal damaged tissues.”

Novartis Confirms Cosentyx Efficiency For Psoriasis Treatment

Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China

Cosentyx is a targeted biologic that specifically inhibits IL-17A, a cornerstone cytokine involved in the inflammation and development of psoriatic disease. It includes psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). IL-17A is produced by both IL-23 dependent and IL-23 independent pathways, by various cells from both the innate immune system, which can be triggered by mechanical stress and the adaptive immune system. Cosentyx inhibits this cornerstone cytokine irrespective of where the IL-17A comes from by acting directly on IL-17A,

Novartis, leading pharmaceutical company announced new data regarding clinical trial conducted on 441 Chinese patients with moderate to severe plaque psoriasis. The Phase III study was focused on investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients reported that, 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. In patients treated with Cosentyx 150mg, 87.8% achieved PASI 75 and 66.4% achieved PASI 90 at week 12.

Cosentyx is a fully human monoclonal antibody neutralizing IL-17A. It has demonstrated rapid, long-lasting efficacy and safety in the treatment of moderate to severe psoriasis, psoriatic arthritis, and the more persistent manifestations of psoriasis, namely scalp, palms, soles and nails, which is backed by a wealth of research with 100 studies. Studies proved that it helps clear or almost clear skin in 8 out of 10 patients within 16 weeks of treatment. Moreover, nearly 100% of response rates are maintained up to 5 years. “Cosentyx continues to deliver what psoriasis patients need – reimagining care to provide clear skin and a complete treatment,” said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology, and China Region Development Head. “We’re excited to report for the first time data for a Chinese population, and to see strong support from the data for Cosentyx.”

Wound Care Biologics Market Best Productivity Supply Chain Relationship, Development by 2026

Wound Care Biologics Market
Wound care biologic products facilitates in innate repair mechanisms, and involves the use of active biological agents such as animal and plant-derived active biomolecules, which exhibit antioxidant, antimicrobial, or anti-inflammatory properties.
Wound care biologics are bioengineered products used for non-healing wounds of the lower extremity. Demand for wound care biologic products is expected to increase significantly as early intervention of diabetic ulcer can prevent severe complications such as infection, hospitalization, and amputation. Wound care biologics market is expected to gain significant traction, as the commercially available skin substitutes have clinical and experimental evidence of efficacy in wound healing.

“The global wound care biologics market was valued at US$ 1.2 billion in 2016 and is expected to exhibit a robust CAGR of 6.9% over the forecast period (2017–2025).”

Request Sample Copy Of This Business Report:

Market Dynamics
Increasing incidences of chronic ulcers, owing to rising prevalence of diabetes, increasing surgical procedures, and rise in trauma cases are major driving factors for growth of wound care biologics market. According to the survey by World Health Organization, 2014, injuries resulting from traffic collisions, drowning, poisoning, falls or burns account for 9% of the global mortality. Also, according to a study by BMJ Journal Injury Prevention, 2013, an estimated 973 million people sustained injuries that warranted some type of healthcare and 4.8 million people died from injuries. The Journal also stated that major injury causes included road injury (29.1%), self-harm (17.6%), falls (11.6%), and interpersonal violence (8.5%). Manufacturers are also focused on extensive research and development to develop new products and expand their product portfolio. For instance, in 2016, Integra LifeSciences Holdings Corporation received FDA approval for Integra Dermal Regeneration Template (IDRT) for the treatment of diabetic foot ulcers that is marketed under the name of Integra Omnigraft Dermal Regeneration Matrix. Moreover, public awareness for biologics has positively contributed to the market growth, as people are opting for enhanced medical care for preventing wounds to minimize the morbidity associated with the formation of chronic wounds. However, higher cost of the biologics and stringent regulatory approvals for launch of innovative tissue engineered products are hindering growth of the wound care biologics market.

Detailed Segmentation:
Global Wound Care Biologics Market, By Product Type:
Biologic Skin Substitutes
Enzyme Based Formulations
Growth factors

Asia Pacific is expected to exhibit significant growth in the global wound care biologics market over the forecast period. This is owing to high prevalence of diabetic patients in Asian countries. According to the Indian Diabetes Research Foundation, 2016, around 60% of the world’s population suffering from diabetes lives in Asia, with around one-half in China and India combined. The Foundation also states that Western Pacific reported over 138.2 million people suffering from diabetes, the number for which is expected to rise to 201.8 million by 2035.

Increasing incidence of chronic wounds and ulcers to accelerate the market growth
Chronic wounds have a significant impact on the health and quality of life of patients and their families, causing pain, emotional stress, restriction on daily activities, depression, distress, and anxiety, with prolonged hospital stay and chronic morbidity. According to the Advances in Wound Care Journal, 2015, chronic leg and foot ulcers last for around 12 months on an average, with recurrence affecting up to 65% of patients, leading to loss of function and decreased quality of life.

Major players operating in the global wound care biologics market are Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amino Technology LLC, and Osiris Therapeutics, Inc.

Colposcope Market Revenue Growth Predicted by 2018-2026

Colposcopy is a diagnostic method useful for the diagnosis and evaluation of cervical intraepithelial neoplasia and preclinical invasive cancer. It allows magnified visualization of the site where cervical carcinogenesis occurs. Colposcope is a magnifying instrument used in the diagnosis of cervical cancer or vaginal cancer. Colposcope can also be used to take small tissue sections for further diagnosis via biopsy. Colposcopy is a diagnostic method usually performed after the Pap smear test. Increasing prevalence of cervical and vaginal cancer is expected to boost demand for colposcopy, in turn, boosting growth of the Colposcope market.

Moreover, increasing number of government initiatives such as screening programmes to increase awareness about cancer is also expected to fuel growth of the colposcope market. Availability of alternative methods for detection of cervical and vaginal cancer such as Pap smear test and HPV test hinder growth of the colposcope market. The high cost of colposcope devices is also a factor expected to hinder market growth.

Download The PDF Brochure:

Colposcope Market Taxonomy:

By Product Type:

  • Optical Colposcope
  • Digital Colposcope

By Portability:

  • Trolley Mounted
  • Chair Mounted
  • Handheld

By End Users:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Others

Colposcope Market Driver

In several emerging economies in Africa and Asia, record high risk of cervical cancer among women, and largely lack detection programmes and efficient screening programmes. In these regions, governmental initiatives for cervical cancer screening and increasing healthcare providers with skills in cervical cancer prevention are important components of global cervical cancer control initiatives which is leading to growth of the colposcope market. According to Centers for Disease Control and Prevention (CDC), 2014 data, 4115 women died due to cervical cancer in the U.S. owing to the growing death rate due to cancer, governments of developed economies are continuously focusing on increasing awareness among the populace about screening programmes and make them accessible, to decrease the rate of mortality caused by genital cancer.

The colposcope market is expected to show potential growth during the forecast period due to rising prevalence of cervical and vaginal cancer, globally. This in turn, is expected to increase the demand for colposcope for diagnostics. For instance, cervical cancer is the fourth most common cancer worldwide among women, with 528,000 new cases and 266,000 deaths in 2012, according to International Agency for Research on Cancer (IARC). Furthermore, advancements in technology also plays an important role in boosting growth of the colposcope market. Currently high cost of these devices and lack of skilled professional are restraints for this colposcope market. Increasing research and development by various manufacturers, to create cost-effective devices, is further expected to propel growth of the market. For instance, in 2017, Duke University in collaboration with 3rd Stone Design, Inc., developed a beta prototype of the Pocket Colposcope, which is significantly less expensive, smaller in size and lighter than traditional clinical colposcope devices.

Colposcope Market – Regional Analysis

The colposcope market is geographically segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America holds a prominent position in the colposcope market, attributed to the presence of major players and high adoption of medical technology in the region. Asia Pacific is expected to hold the fastest-growing market for colposcope due to high prevalence of cervical cancer in low and middle income countries. According to National Center for Biotechnology Information, in 2014, 122,844 women are diagnosed with cervical cancer every year in India, whereas 432.2 million women aged 15 years or above are at risk of developing cancer. This in turn, is expected to favor growth of colposcope market.

Colposcope Market – Competitors

Major players operating in the colposcope market include DySIS, CooperSurgical, Atmos, Olympus, Karl Kaps, McKesson, Danaher, and Carl Zeiss.

The Future of Healthcare Polymerase Chain Reaction Market Is Closer Than You Think

Polymerase chain reaction (PCR) is used to amplify a specific segment of DNA through a thermal cycling protocol. Continuous technological advancement in the field of polymerase chain reaction are aimed to improve specificity, scalability and reliability in DNA amplification and thereby creating millions of amplicons of a target sequence in a short period of time. PCR is used for various applications, including the detection of pathogenic bacteria, disease diagnosis, molecular and genetic research, forensic DNA profiling, and parental testing. Rapid technological advancement in the polymerase chain reaction to deliver highly sensitive and optimized detection instrument, increasing prevalence of chronic and infectious disease, and growing research funding in gene therapy and molecular testing is projected to drive growth of the polymerase chain reaction market over the forecast period.

Request For Sample Copy of This Research Report:

Market Dynamics

The global polymerase chain reaction market is projected to witness significant growth over the forecast period, owing to its wide and increasing applications in various fields, which include diagnosis of infectious diseases, such as middle ear infections, tuberculosis, Lyme disease, in forensics, including DNA fingerprinting, paternity testing and in various other molecular research applications, such as DNA sequencing, DNA cloning, and gene expression. Polymerase chain reaction is used for diagnosis of genetic disease, allowing to detect inherited genetic change or spontaneous genetic mutation.

PCR is used in personalized medicine to help patients in selecting certain treatments, such as in cancer when patients have a genetic change that makes a patient more or less likely to respond to a certain treatment. Polymerase chain reaction is used to study the molecular characteristics in cancer patients, in order to deliver tailored cancer therapy in lung and colorectal cancer. Real-time PCR offers higher sensitivity and specificity in various range of nucleic acid amplification, which is used in wide research areas including infectious disease research, translational medicine to applied biology. Furthermore, technological advancement in the PCR reagents, assay, instruments and analysis tools, help to provide more customized results in various research areas, such as stem cell research, oncology and genetic disease research, pharmaceutical analytics, pharmacogenomics, plant science research and agriculture biotechnology. Such wide numbers of PCR applications in the different field of healthcare and medical research areas, are estimated to augment growth of the polymerase chain reaction market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the polymerase chain reaction market and its market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

Increasing Prevalence of Chronic and Infectious Disease are Driving Growth of Polymerase Chain Reaction Market

Polymerase chain reaction is increasingly used in clinical diagnosis of infectious disease, nucleic acid amplification, paternity testing, DNA fingerprinting, detection and diagnosis of infectious disease, quality control, and personalized medicine. For instance, according to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths due to the influenza infection were registered in 2015, in U.S. According to the World Health Organization (WHO), in 2015, around 32,000 estimated deaths were reported from tuberculosis and around 3, 23,000 new cases of TB cases were registered in the European region. According to the National Ambulatory Medical Care Survey: 2015 data findings, 16.8 million visits to physician offices for infectious and parasitic diseases were registered in the U.S.

Key players operating in polymerase chain reaction market include F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux, S.A., Enzo Life Science, Inc., Abbott Laboratories, Takara Bio Inc., Becton, Dickinson and Company, and Danaher Corporation.

Trigeminal Neuralgia Treatment Market Statistics And Research Analysis Released In Latest Report

Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic pain disorder that affects the fifth cranial or trigeminal nerve. It causes inflammatory conditions due to systemic diseases including Lyme disease, sarcoidosis, and multiple sclerosis. There is also an association with collagen vascular diseases including systemic lupus erythematosus and scleroderma. The condition is treated on an outpatient basis, except till neurosurgical intervention is required. Its management must be customized individually, based on the patient’s general condition and age. However, the exact cause of the condition is unknown.

Download The PDF Brochure:

Trigeminal neuralgia treatment market can be subdivided into drug therapy and surgery. Trigeminal neuralgia surgery is undertaken if medication causes troublesome side-effects or does not work. There are three main types of surgeries, rhizotomy, stereotactic radiosurgery and microvascular decompression. Rhizotomy is an outpatient procedure performed under general anesthesia. It involves destroying the fibers within the trigeminal nerve that are carrying pain signals. Microvascular decompression is the most curative and permanent surgery for trigeminal neuralgia treatment. It is usually offered to patients who are not too older and are in reasonably good health.

Idiopathic trigeminal neuralgia, for which cause is unknown, is mostly treated with a single anticonvulsant medication such as carbamazepine. Carbamazepine, oxcarbazepine, gabapentin, lamotrigine or baclofen are some drugs used in treatment of TN. Carbamazepine often works well for trigeminal neuralgia and can ease symptoms of TN within 1-2 days. Its dose varies from patient to patient. Other medicines that ease nerve impulses can be used in combination of two drugs if one alone does not help. However, these medicines can cause various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness. Moreover, these drugs lose their effectiveness with time, requiring greater number of medications or higher doses taken together. Some patients experience side effects serious enough to discontinue the medication. Furthermore, some issues about diagnosis, surgical and pharmacological treatment of TN are unsettled. Major issues to address in the management of patients with TN include persistent side effects from medication, continued delays in diagnosis, and a lack of psychological support. All these factors are expected to hinder growth of the market during the forecast period. However, the European Federation of Neurological Societies and the American Academy of Neurology launched a combined task force to prepare general guidelines for the management of trigeminal neuralgia.

Market Dynamics

Increasing number of geriatric population is expected to drive growth of the trigeminal neuralgia treatment market worldwide as elderly people are more prone to get affected. Trigeminal neuralgia majorly affects people with age of 50 or more. It can occur at any age, including infancy. Young adults suffering from multiple sclerosis have high risk of developing TN. According to national Institute of Neurological Disorders and Stroke (NINDS), the number of new cases is around 12 per 100,000 each year. The condition is more common among women than in men. In young individuals, the cause is mostly idiopathic, but as compared to elderly, adult cases are mostly caused due to central nervous system damage similar to individuals with multiple sclerosis. The condition is extremely rare in children. However, various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness caused due to medications can negatively impact growth of the market. Furthermore, these drugs lose their efficacy over time.

Regional Insights

Regional segmentation of trigeminal neuralgia market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America trigeminal neuralgia treatment market is expected to hold a significant position due to increasing awareness among people about the condition. The Facial Pain Research Foundation and Intl Trigeminal Neuralgia and Me organized the International Trigeminal Neuralgia Awareness Day on October 7th every year. The market in Asia Pacific region is expected to grow at lucrative rate, owing to large number of population. According to a study published by Omics International, in China an estimated 4,458,090 people that is 2.6% among the total population are suffering from this condition. Market in emerging economies offer opportunities to market players in trigeminal neuralgia treatment market.

Competitive Analysis

Major players operating in the trigeminal neuralgia treatment market include Allergan Plc, Merz Pharma GmbH & Co., Biogen, Inc., Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina Inc., Pfizer Inc., Novartis, and GlaxoSmithKline Plc. Few industry player focus on developing technologically advanced products that eliminate the need for drugs and surgery in acute pain occurred due to TN. For instance, The PainShield (NanoVibronix) transmits slow release ultrasound to deliver fast pain relief for nerve and soft tissue damage. It is extremely effective and provides trigeminal neuralgia acute pain relief and treatment.

Request For Sample Copy of This Research Report:

Anaplastic Astrocytoma Treatment Market Size & Share to See Modest Growth Through 2026

Astrocytoma is a medical condition that develops from astrocytes, a star-shaped brain cells. The disease has been categorized into four different groups based on reproduction rate of the cell, and its capability to spread in nearby tissues. Grades I and Grades II astrocytomas are non-malignant, and can be referred to as low grade. However, Grades III and Grades IV are malignant, and has the capacity to spread quickly. With time, lower grade astrocytoma can change to high grade astrocytoma. Grade III astrocytomas are also called as anaplastic astrocytomas. Anaplastic Astrocytoma is a rare medical condition, and can be divided into two categories – IDH-mutant, IDH-wildtype. IDH1 is a gene that encodes for a metabolic enzyme called isocitrate dehydrogenase 1.

According to American Brain Tumor Association, about 25,000 new cases of primary malignant brain tumors were diagnosed in the U.S. in 2016. Moreover, about 50% of gliomas are glioblastomas. Occurrence of anaplastic astrocytomas is more common in adults compared to children, according to American Brain Tumor Association (ABTA). The ABTA estimates that anaplastic astrocytomas in people aged 30-35 years accounted for 17% of primary malignant brain tumors, however, only 9% of tumor in children are glioblastomas.

Download The PDF Brochure:

Anaplastic Astrocytoma Treatment Market: Driver

Increasing number of drug candidate in pipeline, which may receive approval over the forecast period is expected to drive growth of the global anaplastic astrocytoma treatment market. Currently, there is only a drug, temozolomide (Temodar), approved by U.S. FDA for Anaplastic Astrocytoma. Temodar is an alkylating agent that has been approved for both conditions, newly diagnosed patients as well as refractory anaplastic astrocytoma patients, who have witnessed disease progression in spite of taking drug containing nitrosourea and procarbazine. However, there are multiple products in pipeline for the treatment of anaplastic astrocytoma. For instance, DCC-2618, a drug candidate developed by Deciphera Pharmaceuticals, Inc. is currently in Phase 1 clinical trials. The drug has also been granted orphan drug designation for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) in September 2017. Moreover, an experimental drug PAC-1 was cleared for the clinical trial of patients with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The trial will determine if the drug candidate is safe to use in combination with a standard chemotherapy drug, temozolomide.

Anaplastic Astrocytoma Treatment Market: Restraint

Currently, there are three main forms of treatment for anaplastic astrocytoma – surgery, radiation, and chemotherapy. Out of these three, surgery is the first line of treatment in most of the cases. Only if, whole tumor cannot be safely excised or removed, patients are advised to go for other method of treatment. This treatment pattern i.e. drugs as second or third line of treatment has hampered the sales of pharmaceutical drugs such as Temodar, which in turn has restrained growth of anaplastic astrocytoma treatment market.

Anaplastic Astrocytoma Treatment Market: Regional Analysis

North America is expected to account for major share in global anaplastic astrocytoma treatment market, owing to higher awareness about rare diseases such as anaplastic astrocytoma, and also, presence of leading clinical-stage companies in the region. For instance, a study sponsored by Burzynski Research Institute, headquartered at Texas, U.S., is testing antineoplaston therapy (atengenal + astugenal) in clinical trials. The study is currently in phase 2 clinical trials. Furthermore, a clinical trial sponsored by Northwell Health in collaboration with Genentech, Inc. (subsidiary of Roche AG) is testing safety and efficacy of Erlotinib for anaplastic astrocytoma. The study is currently in Phase 1/2. Approval of these pipeline products over the forecast period would boost growth of North America anaplastic astrocytoma treatment market.

Moreover, the approval of generics for temozolomide will play a vital role in increasing adoption of drug, especially in emerging economies in regions such as Asia Pacific and Latin America. In 2016, FDA approved the Amerigen Pharmaceuticals Limited’s generic version of Temodar. The company’s main facility is in Jiangsu Province, China. Leading global generic players such as Mylan N.V. has also received approval for generic version of Temodar in July 2016. The entry of generic drugs is expected to support growth of the anaplastic astrocytoma treatment market.

Anaplastic Astrocytoma Treatment Market: Key Players

Key players operating in anaplastic astrocytoma treatment market includes Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer, Inc., and Novartis AG. Roche AG has also product for anaplastic astrocytoma in pipeline, currently. Moreover, medium-sized generic manufacturers such as Perrigo Company Plc and Cipla Ltd. also have presence in the market.